Aksys
This article was originally published in The Gray Sheet
Executive Summary
Enrolls 24 patients in a six-month clinical study of its PHD personal hemodialysis system to support a future 510(k) submission to FDA. The three-phase trial is being conducted at dialysis clinics located in Washington, Missouri and Mississippi